Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 1
2022 3
2023 7
2024 4
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
Pulmonary Embolism: Don't Start Me to Talkin'.
Barco S, Fumagalli RM. Barco S, et al. Among authors: fumagalli rm. Hamostaseologie. 2024 Jun;44(3):166-168. doi: 10.1055/s-0044-1780534. Epub 2024 Jul 1. Hamostaseologie. 2024. PMID: 38950527 Free article. No abstract available.
Long-term course of ambulatory patients with COVID-19 initially treated with enoxaparin vs no anticoagulation: final analysis of the OVID (enoxaparin for outpatients with COVID-19) randomized trial.
Fumagalli RM, Voci D, Bikdeli B, Bingisser R, Colucci G, Forgo G, Gerardi T, Gerber B, Grigorean A, Klok FA, Righini M, Robert-Ebadi H, Stortecky S, Ulrich S, Wolf S, Wyss D, Hobohm L, Kucher N, Barco S; OVID investigators. Fumagalli RM, et al. Res Pract Thromb Haemost. 2024 Jul 26;8(5):102534. doi: 10.1016/j.rpth.2024.102534. eCollection 2024 Jul. Res Pract Thromb Haemost. 2024. PMID: 39252826 Free PMC article.
Enoxaparin for outpatients with COVID-19: 90-day results from the randomised, open-label, parallel-group, multinational, phase III OVID trial.
Voci D, Götschi A, Held U, Bingisser R, Colucci G, Duerschmied D, Fumagalli RM, Gerber B, Hasse B, Keller DI, Konstantinides SV, Mach F, Rampini SK, Righini M, Robert-Ebadi H, Rosemann T, Roth-Zetzsche S, Sebastian T, Simon NR, Spirk D, Stortecky S, Vaisnora L, Kucher N, Barco S; OVID investigators. Voci D, et al. Among authors: fumagalli rm. Thromb Res. 2023 Jan;221:157-163. doi: 10.1016/j.thromres.2022.10.021. Epub 2022 Nov 12. Thromb Res. 2023. PMID: 36396519 Free PMC article. Clinical Trial.
Blood cell differential count discretisation modelling to predict survival in adults reporting to the emergency room: a retrospective cohort study.
Fumagalli RM, Chiarelli M, Cazzaniga M, Bonato C, D'Angelo L, Cavalieri D'Oro L, Cerino M, Terragni S, Lainu E, Lorini C, Scarazzati C, Tazzari SE, Porro F, Aldé S, Burati M, Brambilla W, Nattino S, Locatelli M, Valsecchi D, Spreafico P, Tantardini V, Schiavo G, Zago MP, Fumagalli LAM. Fumagalli RM, et al. BMJ Open. 2023 Nov 22;13(11):e071937. doi: 10.1136/bmjopen-2023-071937. BMJ Open. 2023. PMID: 37993167 Free PMC article.
Enoxaparin for symptomatic COVID-19 managed in the ambulatory setting: An individual patient level analysis of the OVID and ETHIC trials.
Barco S, Virdone S, Götschi A, Ageno W, Arcelus JI, Bingisser R, Colucci G, Cools F, Duerschmied D, Gibbs H, Fumagalli RM, Gerber B, Haas S, Himmelreich JCL, Hobbs R, Hobohm L, Jacobson B, Kayani G, Lopes RD, MacCallum P, Micieli E, Righini M, Robert-Ebadi H, Rocha AT, Rosemann T, Sawhney J, Schellong S, Sebastian T, Spirk D, Stortecky S, Turpie AGG, Voci D, Kucher N, Pieper K, Held U, Kakkar AK; OVID and ETHIC Investigators. Barco S, et al. Among authors: fumagalli rm. Thromb Res. 2023 Oct;230:27-32. doi: 10.1016/j.thromres.2023.08.009. Epub 2023 Aug 18. Thromb Res. 2023. PMID: 37625200 Free article.
13 results